31 October 2018 - - Todd S. Young is leaving as US-based Acadia Pharmaceuticals Inc.'s (NASDAQ: ACAD) executive vice president and chief financial officer to join another healthcare company, the company said.

Elena Ridloff, CFA, senior vice president, Investor Relations will serve as the company's Interim chief financial officer.

Acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

The company has developed and is commercialising the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

In addition, Acadia has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder and Rett syndrome.

Nuplazid is the first FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis.

It is a non-dopaminergic, selective serotonin inverse agonist preferentially targeting 5-HT2A receptors that are thought to play an important role in Parkinson's disease psychosis.

Nuplazid is an oral medicine taken once a day with a recommended dose of 34 mg. Acadia discovered and developed this new chemical entity and holds worldwide rights to develop and commercialise Nuplazid.